An interventional study of qEEG-neurofeedback and SHAM qEEG-neurofeedback in Post-Acute COVID-19 Syndrome, Long COVID and Brain Fog, sponsored by Jade Carvalho Da Silva. Completed at 1 site in Brazil. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Jade Carvalho Da Silva · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil — 9 open to participants now, 10 under way, 2 of them phase 3. Post-Acute COVID-19 Syndrome · Brazil.
Among the 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil, this one is the 12th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2025, is one of 12 with no phase, and was the 20th registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →9 of the 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil are open now. Recruiting first, the newest first:
Douglas D. Fraser · Sites in Brazil, United States, Canada and 4 more countries
Ages 18–65
University of Nove de Julho · Sites in Brazil
Ages 18+
University of Nove de Julho · Sites in Brazil
Ages 18+ · Healthy volunteers
University of the State of Santa Catarina · Sites in Brazil
Ages 20–80 · Healthy volunteers
Federal University of São Paulo · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 57 across the 18 interventional studies, 72 across the 3 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 21 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Jade Carvalho Da Silva as lead sponsor.
Jade Carvalho Da Silva has 1 study filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Post-Acute COVID-19 Syndrome with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The pandemic has highlighted social, economic, educational, and political issues that have affected the health and quality of life of millions of Brazilians. Currently, attention and memory impairment remains predominant among the cognitive symptoms of Coronavirus observed in adults. The persistance of the reffered impairment after 12 weeks of COVID-19 is known as cognitive impairment in post-COVID-19 syndrome. Despite studies indicating the negative effects of COVID-19 on attention and memory, there is a gap in the literature regarding the investigation of QEEG-neurofeedback training (QEEG-NFT) efficacy for neurocognitive rehabilitation in COVID survivors with brain fog. In this context, quantitative electroencephalogram neurofeedback training (EEGq-NFT) is a promising non-invasive intervention designed to improve cognition, such as attention and working memory. By modifying electrophysiological patterns in the cerebral cortex. Considering the information presented, the question is what is the efficacy of EEGq-NFT training in rehabilitating attention and working memory in adults with cognitive impairment due to post-COVID-19 syndrome. This study aims to verify the efficacy of EEGq-NFT to rehabilitate cognition, more specifically attention, working memory and speed processing, in adults with cognitive impairment related to post-COVID-19 syndrome. A total of 40 participants were be randomly assigned to an EEGq neurofeedback training group (n = 13), an active control group called SHAM EEGq-neurofeedback (n = 13), and a waiting list control group (n = 14). The theta/beta ratio reduction protocol at frontal and central areas were used, with a total of 13 sessions. The Psychological Battery of Attention 2 (BPA-2), Digit Span Test (DST) and Five Digit Test (FDT) were employed to measure attention, working memory and speed processing levels. Statistical analyses were performed using JASP and R softwares with statistical significance set at p \< 0.05 for a 95% confidence interval. The research followed all ethical standards for studies involving human subjects and was submitted for review and approval at the Research Ethics Committee.
The criteria were revised on the registry on Sep 25, 2026. See what changed
The inclusion criteria were: 1) Present a history of positive diagnosis of COVID, 2) Present post-COVID-19 syndrome, as defined by the United Kingdom's National Institute for Health and Care Excellence (NICE), 3) Present a score equal or lower than 26 on the (MoCA), 4) Be over 18 years old and under 60 years old, 5) Not use psychoactive substances, such as methylphenidate, benzodiazepines and hypnotics, 6) Not have a history of neurological and/or psychiatric diseases prior to or subsequent COVID-19, 7) Authorize participation in the study through the form. The exclusion criteria were: 1) Present physical or cognitive repercussions resulting from other diagnoses prior to or subsequent to COVID-19, 2) Discontinue participation in the study, 3) Present a history of attention and memory impairment prior to the diagnosis of COVID-19.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The participants were submitted to a qEEG-neurofeedback intervention in order to verifify its feasibility to enhance cognition. The theta/beta ratio reduction protocol at electrodes Fp1, Fp2, Fz, F3, F4, Cz, C3, C4 were performed, with 10 sessions of qEEG-neurofeedback training, 2 sessions for pre and post test, and 1 session for follow-up after 30 days of intervention. The Psychological Battery of Attention 2 (BPA-2), Digit Span Test (DST) and Five Digit Test (FDT) were employed to measure attention and working memory levels. The Montreal Cognitive Assessment (Moca) were used for neurological and cognitive assessment.
Behavioral: qEEG-neurofeedback
Behavioral: SHAM qEEG-neurofeedback
The participants were submitted to a qEEG-neurofeedback intervention in order to verifify its feasibility to enhance cognition. The theta/beta ratio reduction protocol at electrodes Fp1, Fp2, Fz, F3, F4, Cz, C3, C4 were performed, with 10 sessions of qEEG-neurofeedback training, 2 sessions for pre and post test, and 1 session for follow-up after 30 days of intervention. The Psychological Battery of Attention 2 (BPA-2), Digit Span Test (DST) and Five Digit Test (FDT) were employed to measure attention and working memory levels. The Montreal Cognitive Assessment (Moca) were used for neurological and cognitive assessment. Participants will receive feedback based on their theta/beta ratio in the frontal and central cortical areas (electrodes Fp1, Fp2, Fz, F3, F4, Cz, C3, C4).
Also known as: Experimental Group, Group 1
The participant were submitted to an inactive qEEG-neurofeedback that appears to be the same as a functional procedure or device. Participants did not receive feedback based on their theta/beta ratio in the frontal and central cortical areas (electrodes Fp1, Fp2, Fz, F3, F4, Cz, C3, C4).
Also known as: SHAM, Group 2
Change from Baseline in the Mean of Psychological Battery of Attention 2 (BPA-2), Digit Span Test (DST), and Five Digit Test (FDT) at 5 weeks
Psychological Battery for Attention Assessment 2 (BPA-2) evaluates overall attention capacity, which is a somatory of specific types of attention, namely, concentrated attention (CA), divided attention (DA) and alternating attention (AA). Digit Span Test (DST) assesses auditory memory and working memory (in direct and reverse order). It consists on sequences of digits, which increase in length, ranging from two to nine items in sequence that must be repeated. The Five Digit Test measures Executive Functions. It involves routines of reading and number counting, with four tasks: reading digits from 1 to 5; counting quantities from 1 to 5; the ability to ignore an automatic processing routine (digit reading) in favor of a controlled one (digit counting) in incongruent stimuli; and the ability to alternate between reading and counting processes. Participants will achieve a response if they score a performance status of to 3 on a classification ranging from 1 (inferior) to 5 (superior).
Time frame: From baseline to the end of treatment at 5 weeks. Finally, at follow-up 30 days post treatment.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Aug 2026, 14 months.
Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 14 months is below that.
Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion May 2026 → Aug 2026 and completion Jun 2026 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →